AbbVie’s PD-1 x VEGF agreement with RemeGen was the first-quarter’s biggest.
ApexOnco Front Page
Recent articles
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
Four months after yielding first-in-human data INCA33890 enters phase 3.
But Tevimbra’s role looks shaky as adverse events loom.
JP Morgan approaches.
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
